Posted by Michael Wonder on 04 Oct 2022
Auvelity, newly approved drug for major depressive disorder, to face payer pricing and reimbursement challenges
3 October 2022 - In August, the FDA approved Axsome Therapeutics’ Auvelity (dextromethorphan/bupropion) extended release tablets for the treatment of major depressive disorder in adults.
Auvelity combines two decades’ old active ingredients; dextromethorphan, which is a cough suppressant, and bupropion, an anti-depressant.
Still, Auvelity is the first orally administered product with a novel mechanism of action to enter the depression market in more than 60 years.
